|  |  |
| --- | --- |
| **Variables** | **N (%)** |
|
| **No. patients (%)** | 322 (100%) |
|   |   |
| **Race, n (%)** |  |
| Caucasian | 291 (90.1%) |
| African-American | 24 (7.4%) |
| Other | 5 (1.6%) |
| Unknown | 3 (0.9%) |
| **Patient age, yr** |  |
| Median (Q1, Q3) | 60 (56-64) |
| **Preoperative PSA (ng/mL)** |  |
| Median (Q1, Q3) | 10.2 (6.5-15.4) |
| **RP Gleason Score, n (%)** |  |
| ≤3+4 | 122 (37.8%) |
| 4+3 | 61 (18.9%) |
| 8 | 39 (12.1%) |
| ≥9 | 101 (31.3%) |
| **Extraprostatic Extension, n (%)** |  |
|   | 232 (71.8%) |
| **Seminal Vesicle Invasion, n (%)** |  |
|   | 87 (26.9%) |
| **Positive Surgical Margins, n (%)** |  |
|   | 89 (27.6%) |
| **Lymph Node Invasion, n (%)** |  |
|   | 63 (19.5%) |
| **Follow-up of censored patients, yr** |  |
| Median (Q1, Q3) | 10 (6-13) |

|  |  |
| --- | --- |
| **Supplementary Table S4. Demographic and clinical-pathologic characteristics of eligible patients in intermediate/high risk radical prostatectomy cohort** |  |